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ABSTRACT
MicroRNA expression is important for gene regulation and deregulated microRNA expression is often observed in diseas-
es such as cancer. The processing of primarymicroRNA transcripts is an important regulatory step inmicroRNAbiogenesis.
Due to lowexpression level and association with chromatin, primary microRNAs are challenging to study in clinical samples
where input material is limited. Here, we present a high-sensitivity targeted method to determine processing efficiency of
several hundred primary microRNAs from total RNA that requires relatively few RNA sequencing reads. We validate the
method using RNA from HeLa cells and show the applicability to clinical samples by analyzing RNA from normal liver
and hepatocellular carcinoma. We identify 24 primary microRNAs with significant changes in processing efficiency from
normal liver to hepatocellular carcinoma, among those the highly expressed miRNA-122 and miRNA-21, demonstrating
that differential processing of primary microRNAs is occurring and could be involved in disease. With our method present-
ed here we provide means to study pri-miRNA processing in disease from clinical samples.
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INTRODUCTION
MicroRNAs (miRNA) are small RNAs that regulate gene ex-
pression at the posttranscriptional level (Kim et al. 2009).
miRNAs are transcribed as primary miRNA (pri-miRNA)
that can be several kilobases long. These transcripts are
processed in the nucleus to 60–90 nt long precursor
miRNA hairpins (pre-miRNA) by the Microprocessor com-
plex. The pre-miRNAs are subsequently exported to the
cytoplasm by export factors where they are processed
into 19–23 nt long mature miRNAs by Dicer and incorpo-
rated into the RISC (RNA-induced silencing complex) to
exert their regulatory function (Kim et al. 2009).
We have previously shown that the endogenous
Microprocessor activity toward individual pri-miRNAs can
be determined using RNA sequencing (Conrad et al.
2014). We identified a signature in the pri-miRNA where
the Microprocessor cleaves the transcript, which can be
quantified to determine processing efficiency (0—not pro-
cessed to 1—fully processed) of individual pri-miRNAs
(Fig. 1A). In our previous work we found that the pri-
miRNA transcript remains rather stable after cleavage by
the Microprocessor and leaves a specific signature (Fig.
1B) that can be used to quantify the fraction of pri-
miRNA cleaved on a steady-state level (Conrad et al.
2014) and dynamically using pulse-chase RNA sequencing
(Louloupi et al. 2017). With these findings we showed on a
transcriptome-wide scale that processing efficiency is
highly variable among different canonical pri-miRNAs
and a major determinant of the expression levels of indi-
vidual mature miRNAs. In addition, we have shown that
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the kinetics of pri-miRNA processing vary between individ-
ual transcripts, including within polycistronic transcripts
(Louloupi et al. 2017). We have shown that the process-
ing efficiency of individual pri-miRNAs is similar between
three different cell lines (HeLa, HEK293 and A549), sug-
gesting that diversity in processing is largely dictated by
the diverse substrate sequences. On the other side, sever-
al studies have shown that cofactors and signaling path-
ways can regulate processing of individual pri-miRNAs or
groups of pri-miRNAs (Davis et al. 2008; Suzuki et al.
2009; Auyeung et al. 2013; Mori et al. 2014; Witteveldt
et al. 2018).
In vitro assays looking at individual pri-miRNA transcripts
have shown pri-miRNA processing to be an actively regu-
lated process that is responsive to TGFß signaling (Davis
et al. 2008), DNA damage (Suzuki et al. 2009) and cell den-
sity (Mori et al. 2014), and a recent study applied our pri-
miRNA processing approach to demonstrate that activa-
tion of the Type I interferon response in cells affects gen-
eral pri-miRNA processing (Witteveldt et al. 2018). Several
Microprocessor cofactors have been identified that influ-
ence pri-miRNA processing (Conrad et al. 2014), modifica-
tion of pri-miRNA with m6A has been suggested to affect
processing of pri-miRNA transcripts (Alarcón et al. 2015;
Han et al. 2020) as has A-to-I editing (Li et al. 2018), and
composition of the sequence flanking the pre-miRNA hair-
pin has been shown to affect efficiency of Microprocessor
cleavage (Auyeung et al. 2013; Conrad et al. 2014).
The major limitation of our established approach to pro-
file pri-miRNA processing transcriptome-wide has been a
requirement for purification of chromatin-associated RNA
and large sequencing depth (for the initial methods devel-
opment we used 200 million reads per sample), making
analysis of clinical samples unfeasible. In thework reported
here we aimed to improve the approach to enable the
analysis of pri-miRNA processing in clinical samples
directly from whole cell total RNA isolated from tissue.
We used a targeted sequencing approach allowing for
quantification of 277 pri-miRNAs with as little as 500 thou-
sand Illumina HiSeq reads, and demonstrate the applica-
bility to clinical samples using RNA from normal liver (NL)
and hepatocellular carcinoma (HCC) samples. We also
identified differentially processed pri-miRNAs between
NL and HCC with a potential implication in disease.
RESULTS
We developed a targeted approach to determine process-
ing efficiency of a library of selected pri-miRNAs from small
amounts of startingmaterial of total RNA and low sequenc-
ing depth. We designed enrichment probes (xGEN lock-
down probes, Integrated DNA Technologies) to enrich
for pri-miRNA sequences from RNA sequencing libraries
(targeting the cDNA of the libraries) covering the se-
quence of the pri-miRNA flanking the region of the pre-
miRNA both upstream and downstream (Fig. 2A). We tar-
geted 32 pri-miRNAs that we had already determined
the processing efficiency for using chromatin-associated
RNA and high sequencing depth (Conrad et al. 2014).
For each pri-miRNA we designed two probes upstream
and two probes downstream from the Microprocessor
cleavage site. Each probe was designed to be comple-
mentary to 120 nt in the region immediately upstream or
downstream from the Microprocessor cleavage sites, re-
spectively. We performed two independent enrichment
experiments on a TruSeq stranded RNA sequencing library
generated from chromatin-associated RNA from HeLa
cells (from Conrad et al. 2014) to test the error range of
the enrichment approach (Fig. 2B). We see a highly repro-
ducible processing efficiency (low error range) between
replicates with a correlation, R=0.995, of processing effi-
ciencies for the 32 pri-miRNAs, demonstrating that the ap-
proach is robust and generates reproducible data.
We next asked how well the enrichment approach reca-
pitulates the processing efficiencies determined by high-
depth sequencing without enrichment (data from Conrad
et al. 2014). From the two independent probe enrichment
replicates we see a high correlation (R=0.92) in processing
efficiency when comparing to previous data of pri-miRNA
processing from purified chromatin-associated RNA (Fig.
A
B
FIGURE1. TheMicroprocessor signature. (A) The general structure of
a pri-miRNA with the hairpin that will become the pre-miRNA upon
Microprocessor cleavage and the mature miRNA sequence are indi-
cated. The equation used to calculate processing efficiency is shown.
Here the ratio of pri-miRNAs covering the pre-miRNA region (repre-
senting unprocessed pri-miRNA) to flanking regions (representing
both processed and unprocessed pri-miRNA) is calculated to show
the fraction of the pri-miRNA that has been cleaved. The processing
efficiency is then calculated as 1 – this ratio. Processing efficiency
will have a value between 1 (fully processed) and 0 (not processed).
(B) Example of the signature where the Microprocessor has cleaved
in an RNA sequencing read density plot, showing the profile that
can be quantified to determine processing efficiency.
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3A; Conrad et al. 2014). Processing efficiencies and cover-
age for the 32 pri-miRNAs are shown in Supplemental
Table 1.
To assess the degree of enrichment achieved with the
targeted approach we calculated RPKM (Reads Per
Kilobase per Million reads) for each of the 32 pri-
miRNAs. As shown in Figure 3B the enrichment is linear
across the expression range of assayed pri-miRNAs (R=
0.998) with a slope of 6670-fold enrichment when using
targeted sequencing of pri-miRNA transcripts. This means
that, in principle, 30,000 reads should be sufficient to
determine processing efficiency for selected pri-miRNAs
when enriched from the chromatin fraction. Assuming
that chromatin-associated RNA constitutes 5% of the total
cellular (nonribosomal) RNA 600,000 reads is necessary to
achieve robust determination of pri-miRNA processing
from total RNA after targeted enrichment.
To address differential pri-miRNA processing in clinical
samples we used RNA from 40 HCC tumors and nine NL
samples. We selected 277 miRNAs with a described in-
volvement in cancer (Farazi et al. 2011; Volinia et al.
2012;Wong et al. 2018) and designed
120-nt xGEN enrichment probes as il-
lustrated in Figure 2A. For each RNA
sample we prepared a TruSeq strand-
ed RNA sequencing library for
Illumina HiSeq 2500 sequencing and
enriched with the probe library as de-
scribed in Materials andMethods. We
aimed for 1 million reads per library
when multiplexing and the final out-
put per library was between 500 thou-
sand and 3 million reads. With this
sequencing depth we detect the pro-
cessing efficiency for 209 pri-miRNAs
in at least two samples, and show dif-
ferential processing between HCC
and NL for 24 of the pri-miRNAs in-
cluded in the analysis (P<0.05,
Wilcoxon rank test) (Fig. 4A; Sup-
plemental Table 2). Following target-
ed enrichment of pri-miRNAs, 33%
of uniquely mapped reads align to
pri-miRNA sequences, demonstrating
an efficient targeted capture despite
low expression levels of the pri-
miRNA transcripts. We see the most
variance in capture from HCC sam-
ples (33±22% of uniquely mapping
reads) compared to NL (33±1% of
uniquely mapped reads), suggesting
more variability in sample quality of
HCC samples. Of particular interest,
we see the most statistically signifi-
cant changes in the processing of
the liver-specific miR122 and the oncomiR miR21 (Fig.
4B), where processing becomes more efficient in HCC. In
NL, around 80% of the pri-miRNA is cleaved by the
Microprocessor whereas in HCC we can observe almost
complete processing (close to 100% of the pri-miRNA is
processed).
DISCUSSION
Here, we have developed a targeted version of our ap-
proach to measure endogenous pri-miRNA processing
for hundreds of different pri-miRNA at a time. Our targeted
approach offers high sensitivity to the selected pri-miRNAs
and allows assessing numerous pri-miRNAs at a time in a
large collection of tissue and clinical samples. The method
is particularly feasible to complement total RNA sequenc-
ing studies as existing RNA sequencing libraries can
directly be used for targeted sequencing of pri-miRNA
transcripts at very low cost once the enrichment probe li-
brary has been designed.
BA
FIGURE 2. Enrichment of pri-miRNAs for determination of processing efficiency. (A)
Schematic of a pri-miRNA and the localization of our enrichment probes. (B) Reproducibility
of processing efficiency for 32 pri-miRNAs in HeLa cells between two independent enrichment
experiments from an RNA sequencing library generated from chromatin-associated HeLa
RNA.
BA
FIGURE 3. Reproducibility and sensitivity of pri-miRNA processing efficiency determination.
(A) Correlation of processing efficiency determined from high-depth sequencing of chroma-
tin-associated RNA (Conrad et al. 2014) and low-depth sequencing of targeted sequencing
of total RNA for two technical replicates. (B) Sensitivity of each approach determined by
RPKM at pri-miRNAs. Slope shows a 6670-fold increase in sensitivity and a corresponding de-
creased need for sequencing depth. RPKM for targeted sequencing is calculated as the aver-
age of two independent enrichment replicates.
Conrad et al.
1728 RNA (2020) Vol. 26, No. 11
While the method provides a reliable measure for pro-
cessing efficiency, it should be noted that some factors
of variability exist, such as stability of pri-miRNAs, degrada-
tion of pri-miRNA ends after cleavage by the Microproces-
sor and sample preparation and storage. The processing
efficiency should therefore be taken as a relative measure
that can identify differential processing efficiencies be-
tween samples.
We see processing efficiencies to be reproducible
across samples, with most variability in the HCC samples.
This is likely a consequence of partial degradation of the
processed pri-miRNA during surgery, purification and stor-
age of patient samples and RNA. This illustrates the need
to include a reasonable panel size of samples to overcome
this variability. Based on mapping of pri-miRNAs in both
NL and HCC samples, the 40 samples used in this study
provide a sufficient panel size. This panel size could vary
dependent on the quality of the samples used.
We show that the targeted approach works well for clin-
ical samples by demonstrating reproducible differential
processing of a number of pri-miRNAs between NL and
HCC. Here, we show that differential pri-miRNA process-
ing occurs between NL and HCC suggesting that the pri-
mary processing step in miRNA biogenesis can impact
gene expression in disease. Our targeted approach offers
the possibility for further studies of pri-miRNA processing
from clinical samples that have so far not been feasible, al-
lowing identification of themolecular consequences of de-
regulated pri-miRNA processing in disease.
MATERIALS AND METHODS
Cell culture
HeLa cells were cultured at 37°Cwith 5%CO2 in Dulbecco’s mod-
ified Eagle’s medium containing 10% FCS and antibiotics.
Chromatin fractionation and RNA
isolation
RNAwaspurified using TRIzol according to
the manufacturer’s recommendations. For
isolation of chromatin-associated RNA we
used one confluent 10 cm dish of HeLa
cells. Cells were trypsinized, washed with
cold PBS and resuspended in cold lysis
buffer (10 mM Tris pH 7.4; 150 mM NaCl;
0.15% NP-40; RNase inhibitor). The sus-
pension was layered over 1 mL sucrose
buffer (10 mM Tris pH 7.4; 150 mM NaCl;
24% sucrose) after incubation for 5′ on ice
and centrifuged for 5 min at 3500g. Super-
natant was discarded and the remaining
nuclear pellet was briefly rinsed with cold
PBS and resuspended in 250 µL Glycerol
buffer (20 mM Tris pH 7.4; 75 mM NaCl;
0.5 mM EDTA; 50% Glycerol). We added
250 µL nuclear lysis buffer (10 mM Tris pH
7.4, 7.5 mM MgCl2, 0.2 mM EDTA, 0.3 M NaCl, 1 M Urea, 1%
NP-40) followed by vortexing for 4 sec. Samples were centrifuged
for 2 min at full speed after incubation on ice for 2′ and the super-
natant containing the nucleoplasmic fraction discarded. The re-
maining chromatin pellet was briefly rinsed with cold PBS and
resuspended in TRIzol for RNA isolation.
Clinical samples and RNA isolation
The clinical samples were obtained directly from the OR
(Operating Room) on ice. All samples were snap frozen in liquid
nitrogen within 30′. The samples were then stored at −80°C
and total RNA isolated with Qiagen RNA purification columns.
Design of capture probes
Capture probes were designed as xGEN Lockdown probes from
IDT with the minimal recommended length of 120 nt. For each
pri-miRNA targeted by the library, we made four probes, two up-
stream and two downstream from the Microprocessor processing
site. The two probes on either side of the Microprocessing site
were designed to be partially overlapping. For some pri-
miRNAs, for example, miR222-3p and miR34-5p, we could only
design one probe with sufficient specificity. Probe sequences
are given in Supplemental Table 3.
Enrichment of RNA sequencing library and NGS
protocol
Targeted RNA sequencing libraries were enriched according to
the xGEN guidelines with minor modifications. In brief, 12 bar-
coded RNA sequencing libraries were pooled and 500 ng of com-
bined libraries used for each target enrichment. Blocking oligos
were added to the pooled libraries, samples were dried in a
SpeedVac and resuspended in Hybridization Buffer including
the custom enrichment probes and hybridized at 65° for 4 h after
a 30 sec incubation at 95°. Probes were received at 3 pmole/
BA
FIGURE 4. Differential pri-miRNA processing between NL and HCC. (A) Heat-map of pri-
miRNA levels of the 24 differentially processed pri-miRNAs between HCC and NL. miRNAs
are shown with the most statistically significant changes between NL and HC at the top
(miR122) and increasing P-values toward the bottom (miR106b). (B) Increased processing effi-
ciency of pri-miRNAs in HCC compared toNL formiR-122 andmiR-21. Shown is the processing
efficiency as determined by RNA sequencing in all 40 HCC or all nine NL samples. (∗∗∗∗) P<
0.0001, Wilcoxon rank test.
Pri-miRNA processing in clinical samples
www.rnajournal.org 1729
probe and resuspended in 30 µL TE to a storage stock at 0.1
pmole/probe. A total of 2 µL of the storage stock was mixed
with 198 µLTE to have the dilution stock at 1 fmole/probe.Weob-
tained the working stock by mixing 4 µL of the dilution stock with
6 µL TE to reach a concentration of 400 amole/probe. For each
capture experiment we added 1 µL of the working stock and 3
µL TE.
Streptavidin beads were washed twice in BeadWash Buffer be-
fore the capture reactionof customenrichmentprobes and the tar-
geted sequencing library. Samples were incubated 45 min at 65°
followed by a normal wash and two times high-stringency heated
washes followed by an additional wash at room temperature and
elution of the captured library with nuclease-free water. The cap-
tured libraries were amplified with a polymerase chain reaction
(PCR) using KAPA HiFi Hotstart polymerase for 14 cycles. The
postcapture PCR fragment was purified with Agencourt AMPure
XP beads before sequencing of the targeted libraries. Library
preparation was performed using the TruSeq Stranded Total
RNA Kit (Illumina). Sequencing was performed on an Illumina
HiSeq 2500 instrument as 2×50 bp stranded sequencing.
Data analysis and calculation of processing efficiency
Raw reads were inspected for quality using FastQC (v0.11.5).
Reads were then trimmedwith skewer (version 0.2.2) for removing
the adapters and low quality reads. Processed reads were aligned
to the reference genome (human, GENCODE release 27,
GRCh38.p10) using STAR aligner (version 2.5.3a). bedtools
“genomecov” was run on the aligned reads with the “-split” op-
tion for calculating the coverage. The coveragewas multiplied for
a scaling factor (using the parameter “-scale”) that is obtained by
dividing 1 billion/(number of mapped reads × read size). The BED
graph was converted to bigWig using bedGraphToBigWig.
Custom scripts were used to calculate read count averages and
the processing efficiency was calculated by counting the reads
covering the pre-miRNA region divided by the reads covering
the two 100 nt flanking regions of the pri-miRNA (starting 20 nt
from the stem to avoid noise in read coverage), and normalized
to the length of each pri-miRNA in nts (Fig. 1A). Pre-miRNAs
were annotated from the sequence of the mature miRNAs so
that each pre-miRNA starts with the first base of the 5P miRNA
and ends with the last base of the 3P miRNA.
DATA DEPOSITION
All sequencing data have been deposited to GEO under acces-
sion numbers GSE148756 and GSE149631.
SUPPLEMENTAL MATERIAL
Supplemental material is available for this article.
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